Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barnett A. H., Wakelin K., Leatherdale B. A., Britton J. R., Polak A., Bennett J., Toop M., Rowe D., Dallinger K. Specific thromboxane synthetase inhibition and albumin excretion rate in insulin-dependent diabetes. Lancet. 1984 Jun 16;1(8390):1322–1325. doi: 10.1016/s0140-6736(84)91820-8. [DOI] [PubMed] [Google Scholar]
- Colwell J. A., Bingham S. F., Abraira C., Anderson J. W., Comstock J. P., Kwaan H. C., Nuttall F. Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care. 1986 Mar-Apr;9(2):140–148. doi: 10.2337/diacare.9.2.140. [DOI] [PubMed] [Google Scholar]
- DiMinno G., Silver M. J., Cerbone A. M., Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood. 1986 Oct;68(4):886–891. [PubMed] [Google Scholar]
- Fuller J. H., Shipley M. J., Rose G., Jarrett R. J., Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet. 1980 Jun 28;1(8183):1373–1376. doi: 10.1016/s0140-6736(80)92651-3. [DOI] [PubMed] [Google Scholar]
- Kannel W. B., McGee D. L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979 Mar-Apr;2(2):120–126. doi: 10.2337/diacare.2.2.120. [DOI] [PubMed] [Google Scholar]
- Patrono C., Daví G. Antiplatelet agents in the prevention of diabetic vascular complications. Diabetes Metab Rev. 1993 Oct;9(3):177–188. doi: 10.1002/dmr.5610090303. [DOI] [PubMed] [Google Scholar]
- Yudkin J. S. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ. 1993 May 15;306(6888):1313–1318. doi: 10.1136/bmj.306.6888.1313. [DOI] [PMC free article] [PubMed] [Google Scholar]